What is Optimal Blood Pressure?

In the last 30 years, the clinical practice guidelines on both sides of the Atlantic have been lowering blood pressure thresholds. From the starting 160 mmHg systolic blood pressure to 130 mmHg or even 120 mmHg. 

Las nuevas guías Europeas de Hipertensión contrastan con las Americanas

In 2017, the American and the ACC/AHA guidelines were the first to lower said threshold, followed by the European ESC/ESH in 2018 and more recently by the National Institute for Health and Care Excellence (NICE) in August 2019.

With several points in common, they also differ in recommendations. The blood pressure target is still controversial, with 120 mmHg in patients for the ACC/AHA, 120-129 for the young and 130-139 mmHg for the elderly in the European guidelines, and the classic 140/90 for the conservative NICE guidelines.

With the kidneys as one of the main blood pressure targets, the new markers of lesion, inflammation and tubule fibrosis could be the ones to tell the adequate blood pressure threshold for each patient. 


Read also: Secondary Prevention: A Responsibility We Should Not Delegate.


The SPRINT study assessed 2377 hypertensive patients measuring alfa1 and beta2 microglobulin concentration, which was associated with major cardiovascular events, while uromodulin showed an inverse correlation.

Alfa 1 microglobulin twice as high as baseline was associated to the classic major events composite (death, infarction, stroke) as well as separate mortality, with 1.25 HR.

A two-fold higher uromodulin concentration was associat3ed to significant reduction of combined events, with HR 0.79, but this was not enough to reduce mortality considered separately. 


Read also: Benefit of Anticoagulation in the Elderly with Atrial Fibrillation.


The clinical value of these markers to adjust the “ideal” threshold in our patients should be further and discussed and studied.

Original Title: What is the optimal blood pressure?Differences between current guidelines and novel insights into kidney injury.

Reference: Thomas F. Lüscher. European Heart Journal (2019) 40, 3443–3446.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Dual Antiplatelet Therapy in Diabetic Patients with AMI: De-Escalation Strategy

Diabetes Mellitus (DM) is a common comorbidity in patients hospitalized for acute coronary syndrome (ACS) of increasing prevalence over the last decade, associated with...

AHA 2025 | OPTIMA-AF: 1 Month vs. 12 Months of Dual Therapy (DOAC + P2Y12) After PCI in Atrial Fibrillation

Concomitant atrial fibrillation (AF) and coronary artery disease is a common occurrence in clinical practice. In these patients, current guidelines recommend 1 month of...

AHA 2025 | OCEAN Study: Anticoagulation vs. Antiplatelet Therapy After Successful Atrial Fibrillation Ablation

After a successful atrial fibrillation (AF) ablation, the need to maintain long-term anticoagulation (AC) remains uncertain, especially considering the very low residual embolic risk...

AHA 2025 | VESALIUS-CV: Evolocumab in High-Cardiovascular-Risk Patients Without Prior MI or Stroke

LDL cholesterol is a well-established factor for cardiovascular disease. Therapy with PCSK9 inhibitors, including evolocumab, has been shown to reduce the risk of cardiovascular...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

Moderate to severe mitral valve regurgitation (MR) continues is still a high prevalence condition with bad prognosis, particularly among the elderly with left ventricular...

EMERALD II: Non-Invasive Coronary Anatomy and Physiology (CCTA) in ACS Prediction

Despite steady progress in secondary prevention and medical treatment optimization (OMT), acute coronary syndrome (ACS) remains one of the leading causes of cardiovascular morbimortality....

Impact of Balloon Post-Dilation on the Long-Term Durability of Bioprostheses after TAVR

Balloon post-dilation (BPD) during transcatheter aortic valve replacement (TAVR) allows for the optimization of prosthesis expansion and the reduction of residual paravalvular aortic regurgitation....